ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Emylif:Zambon Svizzera SA
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
N07XX02 - RiluzoleATC-DDD Version 2016. Source: WHO
N - Nervous System
 
N07 - Other Nervous System Drugs

This group comprises other nervous system drugs, which cannot be classified in the preceding 2nd levels in ATC group N.

N07X - Other Nervous System Drugs
 
N07XX - Other Nervous System Drugs

This group contains substances, which cannot be classified in the preceding groups.
Combinations of metenkefalin and tridecactide is classified in N07XX (no ATC 5th level).
Combinations of dextromethorphan and quinidine are classified in N07XX59.
Dimethyl fumarate indicated for multiple sclerosis or plaque psoriasis is classified in L04AX.
All products containing tafamidis, regardless of indication, are classified here.
Calcium, magnesium and potassium salts of oxybate are classified in N07XX04 - sodium oxybate.

The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.

N07XX02 - Riluzole
Concentr.Adm.RouteNote
 O 
2024 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home